Krystal BiotechFRA:4KB -2.27%58 PS Ratio is 27.11 as of Jul. 02, 2026, which is 26% above its 10-year median of 21.47. GuruFocus rates FRA:4KB with a GF Score™ of 58/100 and a GF Value™ of €272.20 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 933 Biotechnology companies, Krystal Biotech ranks worse than 71.38% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Krystal Biotech's share price is €322.80.
Krystal Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 was €11.91. Hence, Krystal Biotech's PS Ratio for today is 27.11.
Warning Sign:
Krystal Biotech Inc stock PS Ratio (=26.84) is close to 1-year high of 26.87.
The historical rank and industry rank for Krystal Biotech's PS Ratio or its related term are showing as below:
FRA:4KB'
s PS Ratio Range Over the Past 10 Years
Min: 11.2 Med: 21.47 Max: 419.12
Current: 26.84
During the past 10 years, Krystal Biotech's highest PS Ratio was 419.12. The lowest was 11.20. And the median was 21.47.
FRA:4KB's PS Ratio is ranked worse than 71.38% of 933
companies
in the Biotechnology industry
Industry Median: 9.53
vs FRA:4KB: 26.84
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Krystal Biotech PS Ratio Related Terms
Krystal Biotech PS Ratio Historical Data
* Premium members only.
The historical data trend for Krystal Biotech's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Krystal Biotech's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Krystal Biotech PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Krystal Biotech's PS Ratio distribution charts can be found below:
* The bar in red indicates where Krystal Biotech's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Krystal Biotech's Share Price of today is €322.80. Krystal Biotech's Revenue per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €11.91.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Krystal Biotech (FRA:4KB) has a PS Ratio of 27.11 as of Jul. 02, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Krystal Biotech and its competitors. This is 26% above median its historical median of 21.47. Over the past decade, Krystal Biotech's PS Ratio has ranged from 11.20 to 419.12. According to the industry distribution chart, Krystal Biotech ranks #666 out of 933 companies in the Biotechnology industry, placing it in the top 71.4%.
Is Krystal Biotech's PS Ratio too high?
Krystal Biotech's current PS Ratio of 27.11 is 26% above median its 10-year median of 21.47. Over the past 10 years, this metric has ranged from a low of 11.20 to a high of 419.12. The Biotechnology industry median PS Ratio is 9.53. Krystal Biotech's value of 27.11 is 184.5% above this industry median. Based on the distribution chart, Krystal Biotech ranks #666 out of 933 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Krystal Biotech has a GF Score™ of 58/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Krystal Biotech's PS Ratio compare to TECH and SMMT?
According to the Biotechnology industry distribution chart, Krystal Biotech ranks #666 out of 933 companies for PS Ratio. This places Krystal Biotech in the lower half of its industry. The industry median PS Ratio is 9.53. Krystal Biotech's value of 27.11 is 184.5% above this benchmark. Historically, Krystal Biotech's own PS Ratio has ranged from 11.20 to 419.12 over the past decade. While the company's 10-year median is 21.47 vs. the industry median of 9.53, Krystal Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.53, based on 933 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Krystal Biotech's current PS Ratio of 27.11 is 184.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Krystal Biotech and its competitors. For the Biotechnology industry, the median PS Ratio is 9.53 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Krystal Biotech's current PS Ratio is 27.11, which is 26% above median its own 10-year median of 21.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Krystal Biotech stock overvalued right now?
Based on GuruFocus' analysis, Krystal Biotech (FRA:4KB) is currently considered Modestly Overvalued. The stock's GF Value™ is €272.20, compared to a current price of €322.80 — trading 18.6% above its estimated fair value. The current PS Ratio is 27.11, which is 26% above median its 10-year median of 21.47 and 184.5% above the Biotechnology industry median of 9.53. Krystal Biotech's overall GF Score™ is 58/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Krystal Biotech (FRA:4KB), the current PS Ratio is 27.11 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Krystal Biotech (FRA:4KB) Overvalued in 2026?
Based on GuruFocus' analysis, Krystal Biotech stock appears to be overvalued.
The current stock price of €322.80 is trading 18.6% above its estimated GF Value™ of €272.20.
GuruFocus considers Krystal Biotech to be Modestly Overvalued.
Key valuation signals for FRA:4KB:
PS Ratio: 27.11 (26% above median its 10-year median of 21.47)
GF Value™: €272.20 vs. price of €322.80 (18.6% above fair value)
Industry Position: 184.5% above the Biotechnology median (#666 of 933)
No single metric tells the full story. See the FRA:4KB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
58GF Score
Get the complete analysis for FRA:4KB
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4KB has been successfully added to your 
